Gilead's stock is up about 4% after sharing new data for cancer drug | The Markets Café
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
Wednesday, September 27, 2023
No Result
View All Result
Subscribe
  • Login
The Markets Café
  • News
  • Politics
  • Markets
    • Stocks
    • Futures
    • Commodities
  • Crypto
    • News
    • Markets
    • NFT
    • DeFi
    • Explained
  • Economy
  • Finance
  • Investing
  • Forex
  • Real Estate
  • Tech
  • VideosHOT
  • Community
  • Charts
  • News
  • Politics
  • Markets
    • Stocks
    • Futures
    • Commodities
  • Crypto
    • News
    • Markets
    • NFT
    • DeFi
    • Explained
  • Economy
  • Finance
  • Investing
  • Forex
  • Real Estate
  • Tech
  • VideosHOT
  • Community
  • Charts
No Result
View All Result
The Markets Café
No Result
View All Result
  • News
  • Politics
  • Markets
  • Crypto
  • Economy
  • Finance
  • Forex
  • Investing
  • Tech
  • Videos
  • Community
Home Investing

Gilead’s stock is up about 4% after sharing new data for cancer drug

by Press Room
August 16, 2022
in Investing
98 5
A A
0
21
SHARES
687
VIEWS
FacebookTwitter

Shares of Gilead Sciences Inc.
GILD,
+5.16%
were up 4.9% in trading on Monday after the company said in a news release that Trodelvy improved overall survival rates in people with HR+/HER2- metastatic breast cancer. Gilead said it already filed an application with the Food and Drug Administration asking the regulator to approve the Trodelvy for this group of patients. It also said it expects to soon share full data from this clinical trial, which will help Wall Street analysts understand how Trodelvy will compete against AstraZeneca’s
AZN,
+0.26%
Enhertu, according to SVB Securities analyst David Risinger. Trodelvy, which was approved to treat metastatic triple-negative breast cancer and metastatic urothelial cancer in 2021, generated about $380 million in sales last year. Raymond James analyst Steven Seedhouse told investors that he expects the FDA to approve Trodelvy for this indication after a six-month review cycle. Gilead’s stock is down 9.1% this year, while the broader S&P 500
SPX,
+0.40%
has declined 10.2%.

Read the full article here

Related Articles

Investing

For This Pro, China’s Slowdown Won’t Hold Back These Luxury Stocks

September 27, 2023
Investing

The Hollywood Writers Strike Is Over. What It Means for Netflix and Disney Stocks.

September 27, 2023
Investing

TrueCar stock down 4% after online car platform gets new CFO

September 27, 2023
Investing

Rocket Lab lowers guidance after launch fail

September 27, 2023
Investing

Peloton names new chief product officer to succeed co-founder

September 27, 2023
Investing

Target to close 9 stores across 4 states, citing theft

September 27, 2023

About Us

The Markets Café

The Markets Cafe is your one stope Finance, Politics and bussines news website, follow us to get the latest news and updates from around the world.

Sections

  • Commodities
  • Crypto Markets
  • Crypto News
  • DeFi
  • Economy
  • Explained
  • Finance
  • Forex
  • Futures
  • Investing
  • Markets
  • News
  • NFT
  • Politics
  • Real Estate
  • Stocks
  • Tech
  • Videos

Site Links

  • Contact
  • Advertise
  • DMCA
  • Submit Article
  • Forum
  • Site info
  • Newsletter

Newsletter

THE MOST IMPORTANT FINANCE NEWS AND EVENTS OF THE DAY

Subscribe to our mailing list to receives daily updates direct to your inbox!

  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact

© 2022 The Markets Café - All rights reserved.

No Result
View All Result
  • News
  • Politics
  • Markets
    • Stocks
    • Futures
    • Commodities
  • Crypto
    • News
    • Markets
    • NFT
    • DeFi
    • Explained
  • Economy
  • Finance
  • Investing
  • Forex
  • Real Estate
  • Tech
  • Videos
  • Community
  • Charts

© 2022 The Markets Café - All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.